The 10-day moving average for RYTM crossed bullishly above the 50-day moving average on February 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
RYTM moved above its 50-day moving average on February 18, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RYTM advanced for three days, in of 292 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 244 cases where RYTM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Momentum Indicator moved below the 0 level on February 13, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on RYTM as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for RYTM turned negative on February 12, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RYTM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RYTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RYTM's P/B Ratio (303.030) is very high in comparison to the industry average of (12.604). P/E Ratio (0.000) is within average values for comparable stocks, (85.387). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.581). RYTM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (30.120) is also within normal values, averaging (252.111).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
a developer of peptide therapeutics for metabolic diseases
Industry Biotechnology
A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with RCKT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then RCKT could also see price increases.
Ticker / NAME | Correlation To RYTM | 1D Price Change % | ||
---|---|---|---|---|
RYTM | 100% | +1.52% | ||
RCKT - RYTM | 48% Loosely correlated | +3.15% | ||
KYMR - RYTM | 46% Loosely correlated | +0.68% | ||
ERAS - RYTM | 45% Loosely correlated | -1.27% | ||
IDYA - RYTM | 45% Loosely correlated | -2.67% | ||
RVMD - RYTM | 43% Loosely correlated | +1.97% | ||
More |